Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / SELDI Phase I: Assay Validation-Prostate

SELDI Phase I: Assay Validation-Prostate

109

It is then the goal of this collaborative project – EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) - to use state-of-the-art protein profiling technology to develop and validate such screening methods

Specific Aim IA/Phase IA - The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC). Specific Aim IB/Phase IB - The EPSIC will synchronize SELDI output at the seven participating institutions using prostate cancer/control samples with verified presence of optimized diagnostic peaks. The reproducibility of QSTAR will also be determined using the same samples and compared to that of the PBS-II data. Specific Aim IC/Phase IC - The EPSIC will implement a seven-center collaboration to synchronize SELDI output using a new and expanded cohort of prostate cancer cases and controls obtained from all sites. The reproducibility of QSTAR will also be determined using the same samples and compared to that of the PBS-II data.
The criteria for agreement among labs is based on the agreement in mass location and agreement in protein intensity. Since the true protein mass is unknown at each protein mass measured from the machine (there is always some measurement error, no matter how small it is), the mass location agreement is determined by the agreement of the locations of peaks between each lab and the reference lab (EVMS) and between each lab and other four labs combined. More specifically, after peak identification and alignment are performed by each lab, the coefficient of variation (CV) and intra-class correlation coefficient (ICC) for peak location measures and for peak intensity measures will be calculated for each peak location. The between-lab variation will be compared to the between-sample variation.

There are currently no biomarkers annotated for this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.